Comparative Pharmacology
Head-to-head clinical analysis: GLUCOPHAGE versus GLUMETZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCOPHAGE versus GLUMETZA.
GLUCOPHAGE vs GLUMETZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin primarily decreases hepatic glucose production (gluconeogenesis) and increases peripheral insulin sensitivity, reducing glucose absorption from the gastrointestinal tract. It activates AMP-activated protein kinase (AMPK), leading to inhibition of gluconeogenic enzymes.
Metformin hydrochloride, a biguanide, improves glucose tolerance in type 2 diabetes mellitus by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity (increasing peripheral glucose uptake and utilization).
500 mg orally once daily, titrate by 500 mg weekly; max 2000 mg/day divided twice daily; extended-release: 500 mg orally once daily, titrate by 500 mg weekly; max 2000 mg/day once daily.
Initial: 500 mg orally once daily with evening meal; increase by 500 mg weekly based on tolerability. Maximum: 2000 mg once daily with evening meal. Extended-release formulation.
None Documented
None Documented
Terminal elimination half-life: 6.2 hours (range 4.0-8.7 h); prolonged in renal impairment (up to 17.6 h at CrCl <60 mL/min).
6.2 hours (terminal) in healthy adults; prolonged in renal impairment (e.g., 18 hours in CrCl <30 mL/min)
Renal elimination of unchanged drug: 90%; fecal: 10% (biliary negligible).
Renal (90% as unchanged drug); fecal (minor, <5%)
Category C
Category C
Biguanide Antidiabetic
Biguanide Antidiabetic